Alignment Healthcare (ALHC) Expected to Announce Quarterly Earnings on Thursday

Alignment Healthcare (NASDAQ:ALHC) will likely be releasing its earnings data after the market closes on Thursday, February 27th. Analysts expect Alignment Healthcare to post earnings of ($0.18) per share and revenue of $677.42 million for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Alignment Healthcare Stock Down 1.8 %

Shares of ALHC stock opened at $13.39 on Wednesday. The stock’s fifty day moving average price is $13.29 and its 200 day moving average price is $11.87. Alignment Healthcare has a 1-year low of $4.46 and a 1-year high of $15.82. The company has a market cap of $2.57 billion, a price-to-earnings ratio of -17.39 and a beta of 1.50. The company has a debt-to-equity ratio of 1.82, a current ratio of 1.60 and a quick ratio of 1.60.

Insider Transactions at Alignment Healthcare

In other news, CEO John E. Kao sold 90,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $11.65, for a total value of $1,048,500.00. Following the completion of the transaction, the chief executive officer now owns 2,363,100 shares of the company’s stock, valued at $27,530,115. The trade was a 3.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Hyong Kim sold 62,574 shares of the company’s stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $12.20, for a total value of $763,402.80. Following the completion of the sale, the insider now owns 470,496 shares in the company, valued at $5,740,051.20. The trade was a 11.74 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 441,002 shares of company stock worth $5,772,726 over the last 90 days. 6.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

ALHC has been the topic of a number of research analyst reports. UBS Group boosted their price target on Alignment Healthcare from $9.00 to $12.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Stifel Nicolaus boosted their target price on shares of Alignment Healthcare from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, January 14th. Barclays raised their price target on shares of Alignment Healthcare from $7.00 to $8.00 and gave the stock an “underweight” rating in a report on Wednesday, October 30th. Finally, Stephens reiterated an “overweight” rating and set a $17.00 price objective on shares of Alignment Healthcare in a research note on Monday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Alignment Healthcare has a consensus rating of “Moderate Buy” and an average price target of $11.88.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.